Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on cardiovascular diseases. The Company is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardio metabolic conditions. The Company's pipeline comprises the EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003. EDG-7500 is a novel, oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction which is being studied in a multipart Phase 2 trial for the potential treatment of obstructive and nonobstructive HCM. The Company is also developing EDG-15400, which is in a Phase 1 trial of healthy adults with the future disease target of heart failure with preserved ejection fraction (HFpEF).
Back to dashboard
Company Information
About this company
Key people
Peter A. Thompson
Independent Chairman of the Board, Co-Founder
Jonathan C. Fox
Independent Director
Christopher Martin
Independent Director
Kevin Koch
President, Chief Executive Officer, Director
Alan Russell
Chief Scientific Officer, Director, Co-Founder
Michael P. Nofi
Chief Financial Officer
Behrad Derakhshan
Chief Operating Officer
John R. Moore
General Counsel
Joanne M. Donovan
Chief Medical Officer
Laura A. Brege
Independent Director
Badreddin Edris
Independent Director, Co-Founder
Click to see more
Key facts
- Shares in issue108.60m
- EPICEWTX
- ISINUS28036F1057
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$4.80bn
- Employees127
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.